NASDAQ : ABEO
Abeona Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.35 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 248.75M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 248.75M |
| Enterprise Value | 121.80M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 57.18M |
| Shares Outstanding | 57.18M |
| Shares Change (YoY) | -1.73% |
| Shares Change (QoQ) | +0.75% |
| Owned by Insiders (%) | 17.42% |
| Owned by Institutions (%) | 49.71% |
| Float | 36.09M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.75 |
| Forward PS | 3.15 |
| PB Ratio | 1.94 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.63 |
| Quick Ratio | 6.32 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -43.13% |
| Return on Assets (ROA) | -24.55% |
| Return on Invested Capital (ROIC) | -31.15% |
| Return on Capital Employed (ROCE) | -54.05% |
| Weighted Average Cost of Capital (WACC) | 11.53% |
| Revenue Per Employee | $112,920 |
| Profits Per Employee | -$278,261 |
| Employee Count | 226 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 8.30 |
Taxes
| Measure | Value |
|---|
| Income Tax | -15.41M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -12.83% |
| 50-Day Moving Average | 5.24 |
| 200-Day Moving Average | 5.49 |
| Relative Strength Index (RSI) | 36.08 |
| Average Volume (20 Days) | 1,054,697 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17.21M |
| Short Previous Month | 16.88M |
| Short % of Shares Out | 30.10% |
| Short % of Float | 47.70% |
| Short Ratio (days to cover) | 11.93 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 25.52M |
| Gross Profit | -10.18M |
| Operating Income | -83.62M |
| Pretax Income | -78.30M |
| Net Income | -62.89M |
| EBITDA | -80.79M |
| EBIT | -83.62M |
| Loss Per Share | -$1.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 146.83M |
| Total Debt | 19.87M |
| Net Cash | 126.95M |
| Net Cash Per Share | $2.22 |
| Equity (Book Value) | 128.06M |
| Book Value Per Share | 2.24 |
| Working Capital | 139.77M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -76.44M |
| Capital Expenditures | -5.09M |
| Depreciation & Amortization | 2.83M |
| Net Borrowing | -5.56M |
| Free Cash Flow | -81.53M |
| FCF Per Share | -$1.43 |
Margins
| Measure | Value |
|---|
| Gross Margin | -39.90% |
| Operating Margin | -327.64% |
| Pretax Margin | -306.81% |
| Profit Margin | -246.42% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.73% |
| Shareholder Yield | 1.73% |
| Earnings Yield | -27.22% |
| FCF Yield | -32.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $18.88 |
| Price Target Difference | 334.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 218.79% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 5, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.11 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |